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The increased efficiency of modern
computer techniques has expanded the
possibilities of mathematical modeling in an
unprecedented way. However, medical and
biologic research has not taken full advan-
tage of these possibilities. Mathematical
models are, in fact, working hypotheses that
require clear formulation and quantitative
definition of factors and relations included in
the model. These requirements may discour-
age biologic and medical research scientists
from using mathematical models because
quantitative data are often not available to
them, or are available only to a limited
extent. However, current computer tech-
niques offer the possibility of quickly testing
different estimates of a realistic, probable
choice. The increased efforts required to
construct mathematical models are amply
rewarded by the quantitative predictions
generated by the models.
In the absence of adequate animal
models, mathematical modeling of  HIV
infection is especially important. Many
adequate models of this infection have been
formulated (e.g., 1-3), but they have had a
relatively small impact on clinical and
experimental research. Mathematical mod-
eling, however, was an integral and impor-
tant part of evaluating recently obtained
data on HIV turnover in infected persons
(4,5).
The Mathematical Model
We had simulated the dynamics of
lymphocytes in immunologic tolerance (6) for
a decade when we became interested in
modeling lymphocyte dynamics in HIV-
infected persons (7,8). The tolerance model
simulates escape from tolerance of a
nonreplicating protein antigen and is based
on the assumption that lymphocytes specific
to the tolerated antigen start to appear when
the concentration of the tolerated antigen
drops below the threshold level required for
tolerance induction in differentiating new
lymphocytes. Our model of HIV infection
concentrated on CD4+  lymphocytes because
the depletion of this T-cell subpopulation,
and the parallel decrease in the helper
activity of T lymphocytes, seemed to be the
major immune system defect caused by HIV
infection. When we started to construct the
model, the widely held view was that the
decrease of this T-cell subpopulation is not
caused by the cytopathic effect of the virus
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because in infected persons too few CD4+
cells expressed HIV. A direct or indirect
effect of HIV products on these cells was,
therefore, considered to cause this depletion
(9).
In both immunologic tolerance and HIV
infection, antigen seemed to  eliminate
lymphocytes: in immunologic tolerance,
lymphocytes carrying the specific antigen
receptor were affected, and in HIV infection,
the entire CD4+ lymphocyte population was
the target of HIV products. The dynamics of
the affected lymphocyte pools were mutually
inverse: in tolerance, the number of specific
lymphocytes increased with time because the
antigen concentration decreased and in HIV
infection, the CD4+  lymphocyte count
decreased because of the rising level of HIV
products as the infection progressed.
In the model, CD4+ cell depletion was
assumed to result, directly or indirectly,
from an effect of HIV products, where HIV
proliferated at the same rate during the
whole course of the infection; therefore, once
a simulated substantial decline of CD4+
lymphocytes started, it progressed rapidly to
their total depletion. However, previous
studies indicated that an early decline in
these cells occurs shortly after infection, is
followed by a period of slow decline, and then
the decline accelerates again about the time
AIDS develops (10,11). However, if we
assume that HIV proliferation is limited by a
helper T-cell-dependent immune reaction,
our model could simulate all the observed
phases of CD4+ cell dynamics well (8,12). In
Figure 1, simulation curves of CD4+  and
CD8+  lymphocytes (Appendix) are compared
with the mean observed values of these cells
in HIV-infected persons (10,12).
The immune reaction limiting HIV
proliferation, postulated in the model, was
assumed to be a specific cytotoxic activity of
T cells that required the cooperation of
helper T cells. However, the model is not
dependent on this assumption, and any T
helper-cell-dependent immune reaction can
play this role. Other mechanisms are
possible candidates for this function. Re-
cently, interest was focused on cytokines
produced by CD8+  lymphocytes that inhibit
HIV proliferation (13,14), an effect discov-
ered much earlier (15,16). As far as this
activity depends on T-helper cells, this
situation can be simulated by our model. If T-
helper cells did not play any substantial role
in this mechanism, our model would not be
applicable.
In our model, CD4+ lymphocyte dynamics
were successfully simulated only if T-helper-
cell activity did not decrease linearly with
the decline of CD4+ lymphocytes but faster
than these T cells. This relation is expressed
by the power coefficient  n in  Equation 6
Figure 1.* Simulated CD4+ and CD8+ lympho-
cyte dynamics in HIV infection compared with
observed mean T-cell values for CD4+ lympho-
cytes (circles) and CD8+ lymphocytes (squares).
Figure 2.* Comparison of only linear (curve 1,
n  =1.0) T-helper activity decrease with non-
linear (standard curve 2, n = 1.6).
*CD4
+ cell observed values are depicted as circles and those of CD8
+ lymphocytes as squares. Both simulated and
observed values are depicted as a percentage of normal CD4+ lymphocyte numbers (the normal value of CD8+
lymphocytes is thus 66.7%).Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 301
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(Appendix),  which must  have a value >1.0
(7,8). If the decrease of helper activity was
assumed to be directly proportional to the
number of CD4+ lymphocytes (n = 1.0), it was
possible to simulate only the initial phase of
the CD4+ dynamics—the early drop of these
cells. Then a permanent steady state of the
CD4+ cell level was established (Figure 2,
curve 1). This finding could be of interest for
elucidating mechanisms involved in the
long-term, and possibly permanent, survival
of some HIV-infected persons (17-19) whose
condition seems to be characterized by an
equilibrium between HIV infection and a
protective immune reaction. Although some
of these persons have CD4+ lymphocyte
numbers in the normal range, their cases do
not necessarily contradict the model’s
prediction of a stabilized HIV infection
because with a small HIV load the steady-
state CD4+ cell numbers might be indistin-
guishable from normal ones, given the broad
range of normal values.
We are not able to ascribe a definite
mechanism to the necessary assumption that
the activity of T-helper cells declines faster
than the number of CD4+ lymphocytes. The
faster decline could be caused by the
disruption of the lymphoid tissue structure
by HIV infection (20). Another possible cause
is the increasing HIV variation as infection
progresses (21), if this variation led to
decreased sensitivity, or even resistance, to
the protective immune reaction of at least a
part of the virus population.
From our model of immunologic tolerance
(6), two compartments of the studied
lymphocytes were retained in the model of
HIV infection (7): mature and  immature
CD4+ cells. We incorporated immature lym-
phocytes in the model of immunologic
tolerance because they were more sensitive
to tolerance induction. The assumption of
immature CD4+ lymphocyte sensitivity to
elimination by HIV did not influence the
simulation results substantially (22); there-
fore, only mature CD4+ cells were considered
to be eliminated by the effect of HIV in most
simulations we carried out, including those
described in this article.
Different mechanisms of CD4+ lympho-
cyte depletion caused by HIV infection were
simulated by various modifications of our
model, which assumed either a direct or
indirect effect of HIV (22). Because no
substantial difference was observed in
simulation results, for convenience reasons,
most of the work, including the examples
presented in this article, assumed that
cytotoxic cells limiting HIV proliferation are
also instrumental in depleting CD4+ lympho-
cytes by eliminating those have HIV
products. This assumption seems to be
supported by recent clinical findings (4,5).
Adleman suggested that the depletion of
CD4+   lymphocytes might activate some
homeostatic mechanism that increases their
production (24). He assumed that this
homeostatic mechanism increased produc-
tion of both CD4+ and CD8+ lymphocytes and
did not discriminate between the two T-cell
subpopulations.
Adleman also suggested that the sub-
stantial and permanent depletion of CD4+
lymphocytes in HIV-infected persons might
activate this mechanism. However, because
only CD4+ cells are destroyed in HIV
infection, the newly produced CD8+ lympho-
cytes would accumulate. An increase in the
number of CD8+ lymphocytes was actually
observed in HIV-infected persons, while the
total number of T cells remained in the
normal range. The increase in the CD8+  cell
count might switch off the homeostatic
mechanism that increases T-cell production,
and as a consequence, cause or at least
aggravate the CD4+ lymphocyte depletion
(24,25). Because this view was supported by
convincing evidence, we incorporated this
feedback mechanism in our model (22). When
we compared quantitatively the simulated
CD8+ cell increase with the observed values,
they did not agree well, especially in later
phases of the infection when the simulated
values continued to increase, while the
observed CD8+ lymphocyte counts started to
decline. When it was assumed that HIV
infection constrained the influx of both CD4+
and CD8+ lymphocytes, satisfactory simula-
tion results were obtained (26) (Figure 1).
Modeling Therapeutic Interventions
Because CD4+ lymphocyte counts are a
good prognostic indicator of HIV infection
(27), our model is suitable for simulating
different therapeutic interventions. TheEmerging Infectious Diseases Vol. 2, No. 4—October-December 1996 302
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model has been used to simulate zidovudine
(AZT) chemotherapy and specific immuno-
therapy, both active and passive (28-30). The
intensity of most therapies we simulated did
not completely eradicate the infection, a
situation common to the treatments now
available. If a therapy that is assumed not to
eradicate HIV infection is simulated to be
administered permanently and to retain
undiminished effectiveness, the observed
overall result (besides slight differences in
the dynamics of the changes induced by the
various therapeutic measures) is the estab-
lishment of a new steady-state level of CD4+
lymphocytes (Figure 3). The height of this
level reflects the effectiveness of the
therapy: the nearer to normal values, the
more effective the interventions. This steady
state is always lower than a normal state.
Even when the therapy is started at a later
stage of HIV infection, the obtained steady
state is the same; its value depends only on
the effectiveness of the therapy, regardless
of the onset of treatment (Figure 3, curves 1
and 2).
However, this result is valid up to a
certain point only: when the CD4+  lympho-
cyte numbers are too low, therapy can no
longer reverse the CD4+ cell depletion; it can
only slow the decrease and does not establish
a steady state (Figure 3, curve 3). The stage
of infection in which depletion cannot be
reversed varies with different therapies and
with different intensities of the same
therapy (e.g., AZT doses). It occurs earlier in
the course of the infection with less effective
treatments than with more effective ones.
Actually, there is a point in the intensity of
each treatment when it is possible to stop
further CD4+ cell decline and establish a
steady state with CD4+ cell numbers
corresponding to their value at the onset of
therapy.
Another aspect of the therapies we
simulated was their temporary application.
If the therapy eliminated the virus com-
pletely, CD4+ lymphocyte counts returned to
normal for good. Our simulations concen-
trated mainly on therapies leading only to
limitation of the viral load, and in conse-
quence, to an increase in the numbers of
CD4+ cells. When the treatment was stopped,
the decline of CD4+ cells started again and
essentially proceeded at the same rate as in
untreated persons (Figure 4). The maximal
increase of CD4+ lymphocytes obtained by
such intervention corresponded to that
induced by a permanent application of a
treatment of the same intensity. Of course, if
the applied treatment did not last long
enough to allow the CD4+ cells to reach that
level, only a lower maximal value was
obtained.
According to the results of our simula-
tions temporary therapy only prolonged
survival, although extended survival could
Figure 3.* Simulated effect of permanent AZT
treatment (x = 0.005) started 2m 5m or 6 years after
the acquisition of HIV infection—curves 1, 2, and 3,
respectively.
Figure 4.* Simulated effect of temporary AZT
treatment (x = 0.005) started 5 years after the
acquisition of HIV infection and lasted 1, 2, or 3 years—
curves 1, 2, and 3, respectively.
*CD4
+ cell observed values are depicted as circles and those of CD8
+ lymphocytes as squares. Both simulated and
observed values are depicted as a percentage of normal CD4+ lymphocyte numbers (the normal value of CD8+
lymphocytes is thus 66.7%).Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 303
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exceed the length of treatment. This
situation is relevant especially to chemo-
therapy that loses effectiveness after a
relatively short time, probably because of
drug resistance acquired by HIV. However,
even immunotherapy cannot be expected to
retain its undiminished effectiveness for a
prolonged period.
Therapeutic Depletion of CD8+ Lymphocytes
It has been suggested that lowering the
number of CD8+  lymphocytes in HIV-
infected persons by administering anti-CD8
antibodies could activate the homeostatic
mechanism, thus increasing production of
both CD4+ and CD8+ T cells (24,25).
However, this mechanism might be blocked
by the high numbers of CD8+ lymphocytes
present in HIV infection, as discussed above.
Therefore, these authors assumed that a
depletion of CD8+ lymphocytes brought about
by administering anti-CD8 antibodies might
unblock this feedback mechanism and that
this could counteract the depletion of CD4+
cells caused by HIV infection.
When this regulatory mechanism was
incorporated in our model, we were able to
simulate this situation (26,30). Reducing
CD8+ lymphocyte values to numbers not
much below normal stops the further decline
in CD4+ cells and brings them to a steady
state, which may be higher than their
pretreatment number (Figure 5). Lower
doses of anti-CD8 antibodies also stopped
further decline of CD4+ cells, but the
achieved steady-state level is lower than in
the illustrated case. On the contrary, the
CD4+ lymphocyte increase is larger with
higher antibody doses. As in other cases of
temporary treatment, the decrease in CD4+
values starts again after anti-CD8 antibody
administration is discontinued.
However, such a therapeutic effect of
CD8+ depletion is achieved only if lymphoid
cells eliminated by the administered anti-
body are assumed not to participate in the
anti-HIV immune reaction that limits virus
proliferation. This is not the case with
cytotoxic T cells, or with CD8+  lymphocytes
responsible for the production of cytokines
that inhibit HIV proliferation. This situation
could also be simulated with our model.
When these cells assumed to cause a
protective immune reaction were also elimi-
nated by the administered anti-CD8 anti-
body, the CD4+  lymphocyte decrease did not
stop; it even accelerated (Figure 6). All doses
of anti-CD8 antibody, even very small ones,
increased the depletion of CD4+ lymphocytes
under this assumption, although the deterio-
rating effect was not so strong when small
doses of antibody were used.
Figure 5.* Simulated CD4+ and CD8+ lymphocyte
dynamics after permanent treatment with anti-CD8
antibodies started 2 years after the acquisition of the
HIV infection. Cells mediating the protective anti-HIV
immune reaction are not affected by this treatment
(rR = 0.007, rC  = 0.0).
Figure 6.* Simulated CD4
+ and CD8
+ lymphocyte
dynamics after permanent treatment with anti-CD8
antibodies started 2 years after the acquisition of the
HIV infection. Cells mediating the protective anti-HIV
immune reaction are also affected by this treatment
(rR = 0.007, rC = 0.007).
*CD4+ cell observed values are depicted as circles and those of CD8+ lymphocytes as squares. Both simulated and
observed values are depicted as a percentage of normal CD4+ lymphocyte numbers (the normal value of CD8+
lymphocytes is thus 66.7%).Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 304
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For the sake of brevity, we refrained from
presenting examples from other models,
although in addition to providing some
quantitative differences in simulated re-
sults, these examples could be of interest in
modeling other aspects of HIV infection (31-
33), and the comparison of other results with
those of our model would add another
dimension to this article. Different models,
or some of their parts, can be combined, and
in this way the actual situation might be
simulated even better; on the other hand, a
particular model might simulate a specific
situation and help clarify some questions
posed by clinical or experimental studies.
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Appendix
The model considers immature and mature CD4+ (P
and  P cells) and CD8+ lymphocytes (R and  R cells).  As
normal values of R cells equal about two thirds of those of
P cells, it is assumed that normal R values correspond in a
similar way to 2/3 of  P cells.  The sizes of these cell com-
partments at time t are described by Eqs. (1)-(4).  The
amount of HIV products at time t is given by Eq. (5).  Fi-
nally, Eq. ( 6) gives the number of cytotoxic T cells specific
for HIV (C cells) at time t.  In the model used, these cells
both limit proliferation of HIV, as indicated in Eq. (5), and
effect destruction of CD4+ cells presenting HIV products
according to Eqs. (1)-(2).
(1)
(2)
(3)
(4)
(5)
(6)
where the influx-constraining function was
Here IP is the influx of P cells, i.e., the rate (all rates
are in days-1) of differentiation of P cells from stem cells, tP
(7)
is the rate of maturation of  P cells into P cells, and tP is the
rate of natural death of P cells; the quantities tR and tR are
defined in a fully analogical way. Further, f is the amplify-
ing coefficient of the linear feedback effect of P and/or R
cell decrease on the influx of P and R  cells at time t.
The quantity cPa(t)C(t) is the rate of elimination of
P cells due to the amount of HIV products a(t) and the
number of cytotoxic T cells C(t) at time t.  Analogously,
cPa(t)C(t) is the rate of elimination of P cells.  The value
a
0 is the function of the infectious dose of HIV, q character-
izes the growth rate of HIV, and g  is the rate of inactiva-
tion of HIV products mediated by cytotoxic C cells. The
maturation of these cells from their precursors is assumed
to be dependent on the encounter with HIV products and
the effect of HIV specific helper T cells.  I
C is the influx of
C cell precursors, e  their maturation rate, a  the prolifera-
tion rate of C cells under the antigenic stimulation by HIV
products and helper T cell influence, and tC their natural
death rate. Helper T cell effect on maturation and prolif-
eration of C cells is expressed by the ratio P(t)/P
0; the co-
efficient  n is introduced to characterize the intensity of
this helper effect.  The value h characterizes HIV-constrain-
ing intensity on the P and R cell influx. Value L defines
the level, where such constraining (limiting) effect of  d(t)
starts. Effects of therapeutic interventions are described
by the following parameters: z - HIV elimination rate by
AZT or passive immunization, l - immune response-en-
hancing factor, and rR- and rC-elimination rates of CD8+
and C cells, respectively, by anti-CD8 antibodies.
If not otherwise stated, the model parameters in simu-
lation runs were selected as follows: tP = 0.2,  tP = 0.01,
tR = 0.2, tR = 0.01, tC = 0.01, IP = 1.0, I
C = 0.2, P0 = 5.0,
P
0 = 100.0, R0 = 3.33, R0 = 66.7, C0 = 0.0, a0 = 0.0005,
f  =  0.01,  a = 0.7, e  = 0.512, g  = 0.3, q  = 0.02, n  = 1.6,
h = 3.5,  L = 3.0. Only mature CD4+ lymphocytes were as-
sumed to be susceptible to HIV products, i.e. cP = 0.0,
c
P = 20.0. As a rule, the parameter e was used for final ad-
justment of the respective simulation run.  If no therapeu-
tic interventions are assumed (l = 1.0, z = 0.0, rR = 0.0,
rC = 0.0), the resulting CD4+ standard curve characterizes
best fit of the observed clinical data.
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